Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maveropepimut-S Combination in Advanced Solid Tumors
NCT03836352Phase 2Active, not recruiting
- Sponsor
- ImmunoVaccine Technologies Inc.
- Start
- Dec 2018
- Primary completion
- Dec 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of maveropepimut-S in ovarian cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), bladder cancer, microsatellite instability-high cancer, sponsored by ImmunoVaccine Technologies Inc.. Started Dec 2018; status: active, not recruiting.
02
Drugs
maveropepimut-S
03
Conditions
ovarian cancerhepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)bladder cancermicrosatellite instability-high cancer
Beyond the preview
Go deeper on NCT03836352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836352.